Efficacy and Safety of Human Intravenous Immunoglobulin 10% (Panzyga®) in Patients with Primary Immunodeficiency Diseases: a Two-Stage, Multicenter, Prospective, Open-Label Study

PURPOSE: To assess the efficacy and safety of panzyga® (intravenous immunoglobulin 10%) in preventing serious bacterial infections (SBIs) in patients with primary immunodeficiency diseases (PIDs), a prospective, open-label, multicenter, phase 3 study and an open-label extension study were undertaken...

Descripción completa

Detalles Bibliográficos
Autores principales: Borte, Michael, Melamed, Isaac R., Pulka, Grazyna, Pyringer, Barbara, Knutsen, Alan P., Ochs, Hans D., Kobayashi, Roger H., Kobayashi, Ai Lan, Gupta, Sudhir, Strach, Magdalena, Smits, William, Pituch-Noworolska, Anna, Moy, James N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5554470/
https://www.ncbi.nlm.nih.gov/pubmed/28755067
http://dx.doi.org/10.1007/s10875-017-0424-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5554470/
https://www.ncbi.nlm.nih.gov/pubmed/28755067
http://dx.doi.org/10.1007/s10875-017-0424-4

Ejemplares similares